The purpose of this study was to further examine potential biomarkers of cognitive aging by looking at the associations among oxidative stress, cognitive abilities, and medication adherence in a community-based sample of middle-aged and older adults (n = 42; mean age = 69 years) prescribed at least one medication for hypertension. In addition to measures described in Part I, “Biomarkers for Cognitive Aging,” a 12-hr urine collection for F2-isoprostanes served as an indicator of oxidative stress. Participants completed a battery of cognitive assessments and 8 weeks of electronic medication monitoring for adherence to one antihypertensive agent. Oxidative stress was significantly associated with logical memory, immediate (r = −.38, p < .01) and delayed recall (r = −.42, p < .01), and recognition memory (r = −.42, p < .01) from the Wechsler Memory Scale III, number of perseveration errors (r = .26, p < .05) and categories achieved (r = −.26, p < .01) on the Wisconsin Card Sorting Test (WSCT), and medication adherence (r = −.34, p <.05). Findings indicate that a biomarker of oxidative stress, F2-isoprostanes corrected for vitamin E, is significantly associated with cognitive measures and a functional outcome.
Asha DeviS. (2009). Aging brain: Prevention of oxidative stress by vitamin E and exercise. The Scientific World Journal, 9, 366–372.
3.
BerrC.BalansardB.ArnaudJ.RousselA. M.AlperovitchA. (2000). Cognitive decline is associated with systemic oxidative stress: The EVA study. Etude du Vieillissement Arteriel. Journal of the American Geriatrics Society, 48, 1285–1291.
4.
BerrC.RichardM. J.RousselA. M.Bonithon-KoppC. (1998). Systemic oxidative stress and cognitive performance in the population-based EVA study. Etude du Vieillissement Arteriel. Free Radical Biology & Medicine, 24, 1202–1208.
5.
ChanP. H. (2001). Reactive oxygen radicals in signaling and damage in the ischemic brain. Journal of Cerebral Blood Flow and Metabolism, 21, 2–14.
6.
CotmanC. W.HeadE.MuggenburgB. A.ZickerS.MilgramN. W. (2002). Brain aging in the canine: A diet enriched in antioxidants reduces cognitive dysfunction. Neurobiology of Aging, 23, 809–818.
7.
CracowskiJ. L.DurandT. (2006). Cardiovascular pharmacology and physiology of the isoprostanes. Fundamental and Clinical Pharmacology, 20, 417–427.
8.
de LeeuwF. E.de GrootJ. C.OudkerkM.WittemanJ. C.HofmanA.van GijnJ.BretelerM. M. (2002). Hypertension and cerebral white matter lesions in a prospective cohort study. Brain, 125, 765–772.
9.
DrogeW.SchipperH. M. (2007). Oxidative stress and aberrant signaling in aging and cognitive decline. Aging Cell, 6, 361–370.
10.
EpelE. S.BlackburnE. H.LinJ.DhabharF. S.AdlerN. E.MorrowJ. D.CawthonR. M. (2004). Accelerated telomere shortening in response to life stress. Proceedings of the National Academy of Sciences of the United States of America, 101, 17312–17315.
11.
FloydR. A. (1999). Antioxidants, oxidative stress, and degenerative neurological disorders. Proceedings of the Society for Experimental Biology and Medicine, 222, 236–245.
12.
FolsteinM. F.FolsteinS. E.McHughP. R. (1975). “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
13.
FosterT. C. (2006). Biological markers of age-related memory deficits: Treatment of senescent physiology. CNS Drugs, 20, 153–166.
14.
FountoulakisK. N.TsolakiM.IacovidesA.YesavageJ.O’HaraR.KazisA.IerodiakonouC. (1999). The validation of the short form of the Geriatric Depression Scale (GDS) in Greece. Aging Clinical & Experimental Research, 11, 367–372.
15.
FusterJ. J.DiezJ.AndresV. (2007). Telomere dysfunction in hypertension. Journal of Hypertension, 25, 2185–2192.
16.
GrecoA.MinghettiL. (2004). Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases. Current Neurovascular Research, 1, 341–354.
17.
HalliwellB.ChiricoS. (1993). Lipid peroxidation: Its mechanism, measurement, and significance. American Journal of Clinical Nutrition, 57, 715S–725S.
18.
HalliwellB.ClementM. V.LongL. H. (2000). Hydrogen peroxide in the human body. FEBS Letters, 486, 10–13.
19.
HalliwellB.GrootveldM. (1987). The measurement of free radical reactions in humans. Some thoughts for future experimentation. FEBS Letters, 213, 9–14.
20.
InselK.MorrowD.BrewerB.FigueredoA. (2006). Executive function, working memory, and medication adherence among older adults. Journals of Gerontology Series B. Psychological Sciences & Social Sciences, 61, 102–107.
21.
JolithaA. B.SubramanyamM. V.Asha DeviS. (2009). Age-related responses of the rat cerebral cortex: Influence of vitamin E and exercise on the cholinergic system. Biogerontology, 10, 53–63.
22.
MorrowJ. D. (2000). The isoprostanes: Their quantification as an index of oxidant stress status in vivo. Drug Metabolism Reviews, 32, 377–385.
23.
MorrowJ. D. (2005). Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arteriosclerosis, Thrombosis & Vascular Biology, 25, 279–286.
24.
OnoderaK.OmoiN. O.FukuiK.HayasakaT.ShinkaiT.SuzukiS.… UranoS. (2003). Oxidative damage of rat cerebral cortex and hippocampus, and changes in antioxidative defense systems caused by hyperoxia. Free Radical Research, 37, 367–372.
25.
PerkinsA. J.HendrieH. C.CallahanC. M.GaoS.UnverzagtF. W.XuY.… HuiS. L. (1999). Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology, 150, 37–44.
26.
QureshiG. A.BaigS.SarwarM.ParvezS. H. (2004). Neurotoxicity, oxidative stress and cerebrovascular disorders. Neurotoxicology, 25, 121–138.
27.
ReynoldsA.LaurieC.MosleyR. L.GendelmanH. E. (2007). Oxidative stress and the pathogenesis of neurodegenerative disorders. International Review of Neurobiology, 82, 297–325.
28.
RobertsL. J.MorrowJ. D. (2000). Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radical Biology & Medicine, 28, 505–513.
29.
RoyallD. R.CabelloM.PolkM. J. (1998). Executive dyscontrol: An important factor affecting the level of care received by older retirees. Journal of the American Geriatrics Society, 46, 1519–1524.
30.
RoyallD. R.CordesJ.PolkM. (1997). Executive control and the comprehension of medical information by elderly retirees. Experimental Aging Research, 23, 301–313.
31.
RoyallD. R.PalmerR.ChiodoL. K.PolkM. J. (2004). Declining executive control in normal aging predicts change in functional status: The Freedom House Study. Journal of the American Geriatrics Society, 52, 346–352.
32.
RoyallD. R.PalmerR.ChiodoL. K.PolkM. J. (2005). Executive control mediates memory’s association with change in instrumental activities of daily living: The Freedom House Study. Journal of the American Geriatrics Society, 53, 11–17.
33.
SnowdonD. A.GrossM. D.ButlerS. M. (1996). Antioxidants and reduced functional capacity in the elderly: Findings from the Nun Study. Journals of Gerontology Series A. Biological Sciences & Medical Sciences, 51, M10–M15.
34.
StilleyC. S.BenderC. M.Dunbar-JacobJ.SereikaS.RyanC. M. (2010). The impact of cognitive function on medication management: Three studies. Health Psychology, 29, 50–55.
35.
TouyzR. M. (2003). Reactive oxygen species in vascular biology: Role in arterial hypertension. Expert Review of Cardiovascular Therapy, 1, 91–106.
36.
VaziriN. D. (2008). Causal link between oxidative stress, inflammation, and hypertension. Iranian Journal of Kidney Diseases, 2, 1–10.
37.
YoungI. S. (2005). Oxidative stress and vascular disease: Insights from isoprostane measurement. Clinical Chemistry, 51, 14–15.
